Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 19/20 | 0.39 |
| ▸ | MPEG1 | Q2M385 | 7/20 | 0.39 |
| ▸ | XIAP | P98170 | 2/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12640816 | 0.83 | PTPN1 (0.42) | ALDH1A1MAPTTDP1THRBALOX15 | |
| SCHEMBL12134627 | 0.79 | MAPT (0.65) | ALDH1A1MAPTTDP1THRBALOX5 | |
| SCHEMBL1187732 | 0.79 | MAPT (0.65) | ALDH1A1MAPTTDP1THRBALOX5 | |
| SCHEMBL1186913 | 0.79 | MAPT (0.65) | ALDH1A1MAPTTDP1THRBALOX5 | |
| SCHEMBL21854615 | 0.79 | MAPT (0.65) | ALDH1A1MAPTTDP1THRBALOX5 | |
| Utreloxastat SCHEMBL1713853 | 0.79 | MAPT (0.65) | ALDH1A1MAPTTDP1THRBALOX5 | |
| SCHEMBL29311908 | 0.79 | MAPT (0.65) | ALDH1A1MAPTTDP1THRBALOX5 | |
| SCHEMBL14894797 | 0.77 | MAPT (0.61) | ALDH1A1MAPTTDP1THRBALOX5 | |
| SCHEMBL1187733 | 0.75 | MAOB (0.38) | MAPTALOX5ALOX15MAPK1 | |
| SCHEMBL20362901 | 0.72 | MAPT (0.46) | ALDH1A1MAPTTDP1THRBALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210322337-A1 | TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS | PTC THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
| EP-1933821-B1 | TAIL VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS | PTC THERAPEUTICS INC (US) | 2020-07-29 | — | — | EP | disclosed |
| EP-1933821-B1 | TAIL VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS | PTC THERAPEUTICS INC (US) | 2020-07-29 | — | — | EP | disclosed |
| US-20180303767-A1 | TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS | BIOELECTRON TECHNOLOGY CORPORATION (US) | 2018-10-25 | — | — | US | disclosed |
| US-10039722-B2 | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells | BIOELECTRON TECHNOLOGY CORPORATION (US) | 2018-08-07 | — | — | US | disclosed |
| US-20180200248-A1 | TREATMENT OF HEARING AND BALANCE IMPAIRMENTS WITH REDOX-ACTIVE THERAPEUTICS | BIOELECTRON TECHNOLOGY CORPORATION | 2018-07-19 | — | — | US | disclosed |
| WO-2015183963-A2 | THERAPEUTIC COMPOSITIONS INCLUDING REDOX-ACTIVE PARABENZOQUINONES AND USES THEREOF | STEALTH PEPTIDES INTERNATIONAL, INC. (MC) | 2015-12-03 | — | — | WO | disclosed |
| US-20140249160-A1 | TREATMENT OF HEARING AND BALANCE IMPAIRMENTS WITH REDOX-ACTIVE THERAPEUTICS | EDISON PHARMACEUTICALS, INC. (US) | 2014-09-04 | — | — | US | disclosed |
| US-20110269776-A1 | TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS | EDISON PHARMACEUTICALS, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| EP-2362726-A1 | TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS | Edison Pharmaceuticals, Inc. (US) | 2011-09-07 | — | — | EP | disclosed |
| WO-2010045220-A1 | TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS | EDISON PHARMACEUTICALS, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
| WO-2009111543-A2 | TREATMENT OF HEARING AND BALANCE IMPAIRMENTS WITH REDOX-ACTIVE THERAPEUTICS | EDISON PHARMACEUTICALS, INC. (US) | 2009-09-11 | — | — | WO | disclosed |
| US-7432305-B2 | Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | EDISON PHARMACEUTICALS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432305-B2 | Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | EDISON PHARMACEUTICALS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432305-B2 | Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | EDISON PHARMACEUTICALS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| EP-1933821-A1 | TAIL VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS | Edison Pharmaceuticals, Inc. (US) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007035496-A1 | TAIL VARIANTS OF REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS | EDISON PHARMACEUTICALS, INC. (US) | 2007-03-29 | — | — | WO | disclosed |
| US-20070072943-A1 | Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | PTC THERAPEUTICS, INC. | 2007-03-29 | — | — | US | disclosed |
| US-20070072943-A1 | Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | PTC THERAPEUTICS, INC. | 2007-03-29 | — | — | US | disclosed |
| US-20070072943-A1 | Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | PTC THERAPEUTICS, INC. | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269776-A1 | TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS | GPX4, TXN2, TXNRD1 | ALDH1A1 386/4885MAPT 3804/4885TDP1 2191/4885 |
| US-20180303767-A1 | TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS | GPX4, TXN2, TXNRD1 | ALDH1A1 386/4885MAPT 3804/4885TDP1 2191/4885 |
| US-20140249160-A1 | TREATMENT OF HEARING AND BALANCE IMPAIRMENTS WITH REDOX-ACTIVE THERAPEUTICS | TXN2, TXNRD2, OTC | ALDH1A1 187/4885MAPT 1557/4885TDP1 698/4885 |
| US-10039722-B2 | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells | GPX4, TXN2, TXNRD1 | ALDH1A1 386/4885MAPT 3804/4885TDP1 2191/4885 |
| US-20180200248-A1 | TREATMENT OF HEARING AND BALANCE IMPAIRMENTS WITH REDOX-ACTIVE THERAPEUTICS | TXN2, TXNRD2, OTC | ALDH1A1 187/4885MAPT 1557/4885TDP1 698/4885 |
| US-20210322337-A1 | TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS | GPX4, TXN2, TXNRD1 | ALDH1A1 386/4885MAPT 3804/4885TDP1 2191/4885 |
| US-20070072943-A1 | Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers | FH, NDUFAB1, ECHS1 | ALDH1A1 465/4885MAPT 1006/4885TDP1 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.